Company intelligence / Profile preview

FUSE-AI

Hamburg, Hamburg, Germany

Ownership: Private
Employees: ~25
Development stage: Other

Overview

FUSE-AI’s radiology software Prostate.Carcinoma.ai has received EU MDR 2017/745 class IIa certification and is authorized as a medical device in the EU, with evidence-based clinical testing and commercial rollout via PACS integrations.[2][3]

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy
Industry: Medical Imaging

Partnerships

PACS and radiology software vendors acting as resellers and integration partners[2][3]

Beyond the preview

Go deeper on FUSE-AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FUSE-AI.

Explore the full profile